Slide 1: Q1 FY25 Results
rsonal use only At the forefront of microbiome diagnostics & therapeutics Q1 FY25 Results ASX: MAP 29 OCTOBER 2024 Authorised for release by the Board of Directors
Slide 2: Disclaimer
Disclaimer 2 This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of release of this Presentation. Microba may in its a
Slide 3: Q1 Results: Financial Highlights
3 rsonal use only Q1 Results Financial Highlights
Slide 4: Q1 Financial Highlights: Revenue and Cash Receipts
Q1 Financial Highlights 4 Significant growth in revenue and cash receipts on PCP rsonal use only Revenue $3.65m (+ 239% vs PCP) | Cash Receipts $5.07m (+184% vs PCP) Q1 Revenue Q1 Cash Receipts (A$m) (A$m) Group Revenue of $3.65m +239% +184% in Q1 FY25 (+239% vs PCP) 3.65 • Personal Testing & Supple
Slide 5: Australian Testing Business: MetaXplore sales momentum
Q1 Financial Highlights 5 Australian Testing Business – MetaXplore sales momentum continues to accelerate rsonal use only 1,832 MetaXplore tests sold (+101% vs PCP) | 487 Ordering Clinicians (+81% vs PCP) MetaXplore Sales - Australia Australia: Continued strong 3500 8000 sales momentum for 3000 7000
Slide 6: UK Business: Sales team in transition
Q1 Financial Highlights 6 UK Business – Sales team in transition phase ahead of MetaXplore Launch in October 31,944 supplements sold (+3.6% vs PCP) | 1,740 tests sold (-13.6% vs PCP) | 771 ordering clinicians (-2% vs PCP) rsonal use only Invivo Supplement Sales Volumes Invivo Test Sales Volumes Tran
Slide 7: Record Q1 revenue, strong momentum in Australia
Q1 Financial Highlights 7 Record Q1 revenue, strong sales momentum in Australia, primed for UK growth rsonal use only Revenue by Quarter $6,000,000 Record Q1 revenue, with MetaXplore adoption and +239% revenue continuing to $5,000,000 accelerate in Australia • offsetting the historical $4,000,000 im
Slide 8: Business Highlights
8 rsonal use only Q4 Results Business Highlights
Slide 9: Recent Milestones & Highlights
Recent Milestones & Highlights 9 TESTING THERAPEUTICS rsonal use only 1) Australia: Continued strong sales momentum for MetaXplore. 1) Inflammatory Bowel - 1,832 tests sold, up 101% vs PCP Disease Program - 487 ordering clinicians, up vs 81% PCP Advancing MAP315 to 2) MetaPanel sales continuing to b
Slide 10: Accelerating growth through strategic appointments
Accelerating growth through 10 strategic appointments rsonal use only Eric Davis Chris Saad Chief Growth Officer Chief Product Officer
Slide 11: Growing MetaXplore sales and clinical adoption in Australia
Growing MetaXplore sales 11 and clinical adoption in Australia MetaXplore Test Sales Volume rsonal use only MetaXplore Ordering Clinicians • 1,832 tests sold, up 101% vs PCP. 723 2,935 • 487 ordering clinicians, up 81% vs PCP 487 • Growth activities: 1,841 1,832 436 - Targeted sales and marketing ac
Slide 12: MetaPanel sales building across Australia
MetaPanel sales building across Australia 12 • Doctor referrals and sales continuing to build rsonal use only monthly across the country, focused around the major east coast states New South Wales, Victoria and Queensland. • Assoc. Prof. Michael Wehrhahn from Douglass Hanly Moir (Sonic Healthcare NS
Slide 13: Transitioning to growth in the United Kingdom
Transitioning to growth in the United Kingdom 13 The fundamental investment thesis of the Invivo Clinical rsonal use only acquisition was the ability to accelerate Microba’s entry of it’s world leading MetaXplore test into the United Kingdom through an established team and customer base. The UK mark
Slide 14: Therapeutic Development Programs continue to advance
14 Therapeutic Development Programs continue to advance rsonal use only Core Discovery Preclinical Phase 1 Phase 2 Program R&D • Inflammatory Bowel Disease Program Undisclosed - Advancing MAP315 to Phase 2. (LBP) IBD (Ulcerative • Immuno-Oncology Program Colitis) MAP 315 - Clinical data and sample s
Slide 15: Key areas of focus and financial snapshot
15 Key areas of focus Financial Snapshot ASX Code MAP Diagnostics rsonal use only Market capitalisation1 $74m Australia - diagnostic sales growth and Shares on issue 447.85m clinical adoption 52-week low / high1 $0.145 / $0.349 United Kingdom - diagnostic test launch Cash Balance (30 Sep 2024) $
Slide 16: Company snapshot
16 rsonal use only Company snapshot
Slide 17: Evidence the gut microbiome is critical to disease
Unequivocal evidence demonstrates that the human gut 17 microbiome is a critical component of disease rsonal use only >21,000 Research publications demonstrate a clear link between chronic diseases and the gut microbiome1 1 PubMed search terms "gut microbiome/microbiota" or "stool microbiome/microbi
Slide 18: Changing the microbiome can change disease outcomes
Changing the microbiome can change disease outcomes 18 >150 Global clinical studies demonstrate that microbiome modulation rsonal use only can influence disease outcomes and clinical symptoms1 Infectious Disease Inflammatory Disease Autoimmune Disease Cancer Mental Health Metabolic Disorders Heart D
Slide 19: Company snapshot
Company snapshot rsonal use only 19 TESTING/ Continuous YoY 2 diagnostic products opening a THERAPEUTICS DIAGNOSTICS revenue growth over new category with an estimated 6 years of operations US $15B global addressable market World-class team Partnerships with market leaders Clinical stage therapeutic
Slide 20: Microba Diagnostics
20 rsonal use only Microba Diagnostics
Slide 21: Our diagnostics vision
21 rsonal use only Our diagnostics vision: To combat disease through microbiome health
Slide 22: Our diagnostics focus
22 Our diagnostics focus rsonal use only Patients suffering from gastrointestinal disease Gastrointestinal Mental Cardiovascular Oncology Longevity Fertility →
Slide 23: Gastrointestinal Disease: half of patients not getting resolution
Gastrointestinal Disease 23 Half of patients are not getting a resolution rsonal use only 37,310,000 47% Patients presenting annually in the US with lower GI abdominal symptoms* 21,500,000 53% Pain, bloating, other Resolved Unresolved 15,370,000 Diarrhoea 440,000 IBD % of patients achieving resoluti
Slide 24: Addressing the GI symptom challenge
Addressing the GI symptom challenge 24 Microba’s comprehensive diagnostic products rsonal use only First line Gastrointestinal pathogen test Launched March 2024 Diagnosing pathogenic causes Stool DNA test. of GI symptoms 175 targets. Expertly curated clinical recommendations for targeted treat
Slide 25: Getting answers for patients in need
Getting answers for patients in need 25 Closing the gap on GI symptom diagnosis and treatment 100% rsonal use only 28% new insights with * 47% 50% ** Unresolved 24% new diagnoses with ** 0% % of patients achieving resolution of gastrointestinal symptoms after 5 years 52% receiving critical new diagn
Slide 26: A multi-billion dollar market opportunity
A multi-billion dollar market opportunity rsonal use only 26 $15B+ US Total Addressable Market* * Assessment of Medicare claims analysis. Estimated Private and Medicaid numbers extrapolated from Medicare claims analysis completed with Boston based MedTech specialist consultancy Veranex Inc. Assumes
Slide 27: Transforming standard of care
Transforming standard of care 27 A paradigm shift rsonal use only “After the first 4 months using the MetaPanel test, 24% of patients have been diagnosed with a pathogen that would have been undiagnosed or experienced delayed time to diagnosis and resolution. This is a breakthrough in infectious Dr
Slide 28: Changing lives every day
Changing lives every day rsonal use only 28 “Before completing the MetaXplore test with my practitioner, my health was in MetaXplore constant distress. I looked and felt bloated all the time, to the point of appearing six patient months pregnant. My severe constipation led to bowel movements only ev
Slide 29: Changing lives every day
Changing lives every day rsonal use only 29 “I have struggled with gastrointestinal symptoms for over half my life. I have MetaXplore tried resolving with many specialists, restrictive eating plans and natural patient therapies. My MetaXplore test this year identified clear problems and a personalis
Slide 30: Microba Therapeutics
rsonal use only Microba Therapeutics
Slide 31: Our Therapeutics Vision
31 rsonal use only Our Therapeutics Vision To combat disease through microbiome health 31
Slide 32: Our primary therapeutic focus
32 Our primary therapeutic focus rsonal use only Clinical: Patients suffering from Inflammatory Bowel Disease Gastrointestinal Autoimmune Oncology Allergy Neuro Cardiovascular → 32
Slide 33: Pioneering an Advanced AI/ML Approach for Precision Live Biotherapeutics
33 Microba is Pioneering an Advanced AI/ML Approach For the Development of Next Generation Precision Live Biotherapeutics rsonal use only Target Prediction Disease Relevant Activity Disease Donor Prevalence Isolation Human Data Driven Precision AI & Machine Microbiome Health Data Learning Therapeuti
Slide 34: Therapeutic pipeline & catalysts
34 Therapeutic pipeline & catalysts rsonal use only Development Core Program Discovery R&D Preclinical Phase 1 Phase 2 Partners MAP 315 Phase 2 IND submission currently (LBP) being compiled IBD (Ulcerative Colitis) Undisclosed (LBP) Pre-clinical biology Undisclosed Immuno-oncology supporting lead (L
Slide 35: Recent IBD Transactions
Recent IBD Transactions 35 Licensee / Licensor / Total Deal Date Deal Type Stage Upfront rsonal use only Acquiror Target Value July 2024 Acquisition Phase 2 - US$3.2B active June 2024 License Preclinical $150m US$1.7B October 2023 Acquisition Phase 2 - US$7.2B complete October 2023 License Phase 2b
Slide 36: Contact
rsonal use only Dr Luke Reid CONTACT Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Chairman Princess Alexandra Hospital pasquale.rombola@microba.com Woolloongabba QLD Australia
Slide 37: Appendix
rsonal use only Appendix 37
Slide 38: Patient pathway: Advancing the standard of care for GI symptoms
Patient pathway — Advancing the standard of care for GI symptoms 38 Functional microbiome Colonoscopy for formal Targeted antibiotic and or GI disorder diagnosis IBD or CRC diagnosis DGBI treatment /or with personalised New Microba and treatment treatment plan care pathway rsonal use only If positiv
Slide 39: Two core business segments driven by a world leading technology
Two core business segments driven by a world leading technology 39 World leading microbiome rsonal use only analysis technology Testing Business Proprietary databank Therapeutics Business Next generation gastrointestinal diagnostics Advanced AI and biostatistics powering a diagnostics and Precision
Slide 40: Developing the 3rd Generation of Microbiome Therapeutics
Microba is developing the 3rd Generation of Microbiome Therapeutics 40 using a human data driven approach 1 First Generation 2 Second Generation 3 Next Generation rsonal use only Faecal Doner Derived & FMT Bacterial Consortia Single Strain & Small Molecule FDA approval Nov 30 2022 Vedanta Bioscience